Neil Versel

Fresh off its July IPO, the Swiss-American company is expanding its technological and geographical footprints with a series of collaborations and partnerships.

The molecular diagnostics company seeks to automate its customers' pipelines with AI and diversify beyond hematology.

The INSIDER algorithm, which grew out of SARS-CoV-2 variant research, looks for shifts in k-mer signatures to streamline the search for novel genomic patterns.

The Canadian company sees nanopore sequencing analysis as an affordable, efficient way to find pathogens without the need for targeted PCR and culture tests.

Software being built or updated for COVID-19 in India and Texas should be adaptable to future biosurveillance needs, developers say.

As organizers develop a plan to sequence 3 million genomes across Africa, bioinformaticians weigh the benefits and risks of such a large, diverse dataset.

Philips has automated the informatics pipeline for NYU Langone's pan-cancer LDT and integrated its Genomics Workspace software with the health system's Epic EMR.

The biopharma companies are looking to accelerate the completion of UK Biobank Exome Sequencing Consortium data analysis to aid drug discovery.

The stock opened at $18 per share, valuing the Switzerland- and Boston-based bioinformatics company at $1.14 billion.

A novel computational method from NuProbe, Rice University, and Microsoft Research relies on a recurrent neural network to predict sequencing depth with high accuracy.